CNS Drugs

, Volume 28, Issue 12, pp 1139–1153 | Cite as

Drug-Induced Cerebellar Ataxia: A Systematic Review

  • J. van Gaalen
  • F. G. Kerstens
  • R. P. P. W. M. Maas
  • L. Härmark
  • B. P. C. van de Warrenburg
Systematic Review

Abstract

Background and Objectives

Cerebellar ataxia can be induced by a large number of drugs. We here conducted a systemic review of the drugs that can lead to cerebellar ataxia as an adverse drug reaction (ADR).

Methods

We performed a systematic literature search in Pubmed (1966 to January 2014) and EMBASE (1988 to January 2014) to identify all of the drugs that can have ataxia as an ADR and to assess the frequency of drug-induced ataxia for individual drugs. Furthermore, we collected reports of drug-induced ataxia over the past 20 years in the Netherlands by querying a national register of ADRs.

Results

Drug-induced ataxia was reported in association with 93 individual drugs (57 from the literature, 36 from the Dutch registry). The most common groups were antiepileptic drugs, benzodiazepines, and antineoplastics. For some, the number needed to harm was below 10. Ataxia was commonly reversible, but persistent symptoms were described with lithium and certain antineoplastics.

Conclusions

It is important to be aware of the possibility that ataxia might be drug-induced, and for some drugs the relative frequency of this particular ADR is high. In most patients, symptoms occur within days or weeks after the introduction of a new drug or an increase in dose. In general, ataxia tends to disappear after discontinuation of the drug, but chronic ataxia has been described for some drugs.

Notes

Acknowledgments

No funding was received for conducting or publishing this review.

Conflict of interest

BvdW is supported by grants from the Royal Dutch Society for Physical Therapy, Radboud University Medical Centre, Gossweiler Foundation, Wetenschapsfonds Dystonievereniging, and Biobanking and Biomolecular Research Infrastructure (BBMRI-NL).

JvG is supported by the Gossweiler Foundation.

FK reports no supporting grants.

RM reports no supporting grants.

LH reports no supporting grants.

Supplementary material

40263_2014_200_MOESM1_ESM.docx (14 kb)
Supplementary material 1 (DOCX 13 kb)
40263_2014_200_MOESM2_ESM.docx (309 kb)
Supplementary material 2 (DOCX 310 kb)

References

  1. 1.
    van de Warrenburg BP, van Gaalen J, Boesch S, Burgunder JM, Durr A, Giunti P, et al. EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood. Eur J Neurol. 2014;21(4):552–62.PubMedGoogle Scholar
  2. 2.
    van Gaalen J, van de Warrenburg BP. A practical approach to late-onset cerebellar ataxia: putting the disorder with lack of order into order. Pract Neurol. 2012;12(1):14–24.PubMedGoogle Scholar
  3. 3.
    Baath NS, Hong J, Sattar SP. Possible carbamazepine toxicity with terbinafine. Can J Clin Pharmacol. 2006;13(2):e228–31.Google Scholar
  4. 4.
    Beattie B, Biller J, Mehlhaus B, Murray M. Verapamil-induced carbamazepine neurotoxicity. A report of two cases. Eur Neurol. 1988;28(2):104–5.PubMedGoogle Scholar
  5. 5.
    Patsalos PN, Stephenson TJ, Krishna S, Elyas AA, Lascelles PT, Wiles CM. Side-effects induced by carbamazepine-10,11-epoxide. Lancet. 1985;2(8469–70):1432.PubMedGoogle Scholar
  6. 6.
    Weisler RH, Keck PE Jr, Swann AC, Cutler AJ, Ketter TA, Kalali AH, et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2005;66(3):323–30.PubMedGoogle Scholar
  7. 7.
    Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010;89(2–3):278–85.PubMedGoogle Scholar
  8. 8.
    Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia. 2007;48(3):497–504.PubMedGoogle Scholar
  9. 9.
    Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P, Group BIAIS. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand. 2009;120(5):281–7.PubMedGoogle Scholar
  10. 10.
    The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. The US Gabapentin Study Group. Epilepsy Res. 1994;18(1):67–73.Google Scholar
  11. 11.
    Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia. 1994;35(4):795–801.PubMedGoogle Scholar
  12. 12.
    Baulac M, Cavalcanti D, Semah F, Arzimanoglou A, Portal JJ. Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. The French Gabapentin Collaborative Group. Seizure. 1998;7(1):55–62.PubMedGoogle Scholar
  13. 13.
    Beran R, Berkovic S, Black A, Danta G, Dunne J, Frasca J, et al. AUStralian study of titration to effect profile of safety (AUS-STEPS): high-dose gabapentin (neurontin) in partial seizures. Epilepsia. 2001;42(10):1335–9.PubMedGoogle Scholar
  14. 14.
    Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage. 2000;20(4):280–5.PubMedGoogle Scholar
  15. 15.
    Fisher RS, Sachdeo RC, Pellock J, Penovich PE, Magnus L, Bernstein P. Rapid initiation of gabapentin: a randomized, controlled trial. Neurology. 2001;56(6):743–8.PubMedGoogle Scholar
  16. 16.
    Hahn K, Arendt G, Braun JS, von Giesen HJ, Husstedt IW, Maschke M, et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol. 2004;251(10):1260–6.PubMedGoogle Scholar
  17. 17.
    Huber B, Tomka-Hoffmeister M. Limited efficacy of gabapentin in severe therapy-resistant epilepsies of learning-disabled patients. Seizure. 2003;12(8):602–3.PubMedGoogle Scholar
  18. 18.
    Irving G, Jensen M, Cramer M, Wu J, Chiang YK, Tark M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain. 2009;25(3):185–92.PubMedGoogle Scholar
  19. 19.
    Kimos P, Biggs C, Mah J, Heo G, Rashiq S, Thie NM, et al. Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial. Pain. 2007;127(1–2):151–60.PubMedGoogle Scholar
  20. 20.
    Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med. 1999;159(16):1931–7.PubMedGoogle Scholar
  21. 21.
    Morris GL 3rd. Efficacy and tolerability of gabapentin in clinical practice. Clin Ther. 1995;17(5):891–900.PubMedGoogle Scholar
  22. 22.
    Perugi G, Toni C, Frare F, Ruffolo G, Moretti L, Torti C, et al. Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? J Clin Psychopharmacol. 2002;22(6):584–91.PubMedGoogle Scholar
  23. 23.
    Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280(21):1837–42.PubMedGoogle Scholar
  24. 24.
    Spira PJ, Beran RG. Australian gabapentin chronic daily headache G. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology. 2003;61(12):1753–9.PubMedGoogle Scholar
  25. 25.
    Steinhoff BJ, Herrendorf G, Bittermann HJ, Kurth C. Isolated ataxia as an idiosyncratic side-effect under gabapentin. Seizure. 1997;6(6):503–4.PubMedGoogle Scholar
  26. 26.
    van de Vusse AC, Stomp-van den Berg SG, Kessels AH, Weber WE. Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. BMC Neurol. 2004;4:13.PubMedCentralPubMedGoogle Scholar
  27. 27.
    Yamauchi T, Kaneko S, Yagi K, Sase S. Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry Clin Neurosci. 2006;60(4):507–15.PubMedGoogle Scholar
  28. 28.
    Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48(7):1308–17.PubMedGoogle Scholar
  29. 29.
    Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010;51(6):958–67.PubMedGoogle Scholar
  30. 30.
    Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Hebert D, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50(3):443–53.PubMedGoogle Scholar
  31. 31.
    Alkawi A, Kattah JC, Wyman K. Downbeat nystagmus as a result of lamotrigine toxicity. Epilepsy Res. 2005;63(2–3):85–8.PubMedGoogle Scholar
  32. 32.
    Beran RG, Berkovic SF, Dunagan FM, Vajda FJ, Danta G, Black AB, et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia. 1998;39(12):1329–33.PubMedGoogle Scholar
  33. 33.
    Betts T, Goodwin G, Withers RM, Yuen AW. Human safety of lamotrigine. Epilepsia. 1991;32(Suppl 2):S17–21.PubMedGoogle Scholar
  34. 34.
    Binnie CD, Debets RM, Engelsman M, Meijer JW, Meinardi H, Overweg J, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res. 1989;4(3):222–9.PubMedGoogle Scholar
  35. 35.
    Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DG, de Korte RA, Meijer JW, Meinardi H, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia. 1986;27(3):248–54.PubMedGoogle Scholar
  36. 36.
    Boas J, Dam M, Friis ML, Kristensen O, Pedersen B, Gallagher J. Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures. Acta Neurol Scand. 1996;94(4):247–52.PubMedGoogle Scholar
  37. 37.
    Brodie MJ. Lamotrigine—an update. Can J Neurol Sci. 1996;23(4 Suppl 2):S6–9.PubMedGoogle Scholar
  38. 38.
    Cocito L, Maffini M, Loeb C. Long-term observations on the clinical use of lamotrigine as add-on drug in patients with epilepsy. Epilepsy Res. 1994;19(2):123–7.PubMedGoogle Scholar
  39. 39.
    Duchowny M, Pellock JM, Graf WD, Billard C, Gilman J, Casale E, et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology. 1999;53(8):1724–31.PubMedGoogle Scholar
  40. 40.
    Herold TJ. Lamotrigine as a possible cause of QRS prolongation in a patient with known seizure disorder. CJEM. 2006;8(5):361–4.PubMedGoogle Scholar
  41. 41.
    Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia. 1989;30(3):356–63.PubMedGoogle Scholar
  42. 42.
    Loiseau P, Yuen AW, Duche B, Menager T, Arne-Bes MC. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res. 1990;7(2):136–45.PubMedGoogle Scholar
  43. 43.
    Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016–26.PubMedCentralPubMedGoogle Scholar
  44. 44.
    Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology. 1993;43(11):2284–91.PubMedGoogle Scholar
  45. 45.
    Messenheimer J, Ramsay RE, Willmore LJ, Leroy RF, Zielinski JJ, Mattson R, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia. 1994;35(1):113–21.PubMedGoogle Scholar
  46. 46.
    Messenheimer JA, Giorgi L, Risner ME. The tolerability of lamotrigine in children. Drug Saf. 2000;22(4):303–12.PubMedGoogle Scholar
  47. 47.
    Nielsen KA, Dahl M, Tommerup E, Wolf P. Comparative daily profiles with different preparations of lamotrigine: a pilot investigation. Epilepsy Behav. 2008;13(1):127–30.PubMedGoogle Scholar
  48. 48.
    Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB, et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer. 2008;112(12):2802–8.PubMedGoogle Scholar
  49. 49.
    Sander JW, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res. 1990;6(3):221–6.PubMedGoogle Scholar
  50. 50.
    Sander JW, Trevisol-Bittencourt PC, Hart YM, Patsalos PN, Shorvon SD. The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Res. 1990;7(3):226–9.PubMedGoogle Scholar
  51. 51.
    Schapel GJ, Beran RG, Vajda FJ, Berkovic SF, Mashford ML, Dunagan FM, et al. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry. 1993;56(5):448–53.PubMedCentralPubMedGoogle Scholar
  52. 52.
    Schaub JE, Williamson PJ, Barnes EW, Trewby PN. Multisystem adverse reaction to lamotrigine. Lancet. 1994;344(8920):481.PubMedGoogle Scholar
  53. 53.
    Schlumberger E, Chavez F, Palacios L, Rey E, Pajot N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia. 1994;35(2):359–67.PubMedGoogle Scholar
  54. 54.
    Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia. 1993;34(2):312–22.PubMedGoogle Scholar
  55. 55.
    Strimel WJ, Woodruff A, Cheung P, Kirmani BF, Stephen Huang SK. Brugada-like electrocardiographic pattern induced by lamotrigine toxicity. Clin Neuropharmacol. 2010;33(5):265–7.PubMedGoogle Scholar
  56. 56.
    Thome-Souza S, Freitas A, Fiore LA, Valente KD. Lamotrigine and valproate: efficacy of co-administration in a pediatric population. Pediatr Neurol. 2003;28(5):360–4.PubMedGoogle Scholar
  57. 57.
    Thome-Souza S, Moreira B, Valente KD. Late adverse effects of the coadministration of valproate and lamotrigine. Pediatr Neurol. 2012;47(1):47–50.PubMedGoogle Scholar
  58. 58.
    Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mullens EL. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain. 1997;73(2):223–30.PubMedGoogle Scholar
  59. 59.
    Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55(2):236–42.PubMedGoogle Scholar
  60. 60.
    Barcs G, Walker EB, Elger CE, Scaramelli A, Stefan H, Sturm Y, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 2000;41(12):1597–607.PubMedGoogle Scholar
  61. 61.
    Guerreiro MM, Vigonius U, Pohlmann H, de Manreza ML, Fejerman N, Antoniuk SA, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 1997;27(3):205–13.PubMedGoogle Scholar
  62. 62.
    Kothare SV, Khurana DS, Mostofi N, Melvin JJ, Marks HG, Valencia I, et al. Oxcarbazepine monotherapy in children and adolescents: a single-center clinical experience. Pediatr Neurol. 2006;35(4):235–9.PubMedGoogle Scholar
  63. 63.
    Sachdeo R, Beydoun A, Schachter S, Vazquez B, Schaul N, Mesenbrink P, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology. 2001;57(5):864–71.PubMedGoogle Scholar
  64. 64.
    Abe K, Okano M, Sasaki H. Phenytoin elimination kinetics in two children with drug intoxication. Eur J Pediatr. 1980;135(1):69–71.PubMedGoogle Scholar
  65. 65.
    Alioglu Z, Sari A, Velioglu SK, Ouml Zmenoglu M. Cerebellar atrophy following acute phenytoin intoxication. J Neuroradiol. 2000;27(1):52–5.PubMedGoogle Scholar
  66. 66.
    Awada A, Amene P, Al Jumah M, Al Beladi K. Residual cerebellar ataxia following acute phenytoin intoxication. Revue Neurol. 1999;155(4):306–8.Google Scholar
  67. 67.
    Baier WK, Beck U, Doose H, Klinge H, Hirsch W. Cerebellar atrophy following diphenylhydantoin intoxication. Neuropediatrics. 1984;15(2):76–81.PubMedGoogle Scholar
  68. 68.
    Baier WK, Beck U, Hirsch W. CT findings following diphenylhydantoin intoxication. Pediatr Radiol. 1985;15(4):220–1.PubMedGoogle Scholar
  69. 69.
    Botez MI, Gravel J, Attig E, Vezina JL. Reversible chronic cerebellar ataxia after phenytoin intoxication: possible role of cerebellum in cognitive thought. Neurology. 1985;35(8):1152–7.PubMedGoogle Scholar
  70. 70.
    Cachat F, Tufro A. Phenytoin/isradipine interaction causing severe neurologic toxicity. Ann Pharmacother. 2002;36(9):1399–402.PubMedGoogle Scholar
  71. 71.
    Curtis DL, Piibe R, Ellenhorn MJ, Wasserberger J, Ordog G. Phenytoin toxicity: a review of 94 cases. Vet Hum Toxicol. 1989;31(2):164–5.PubMedGoogle Scholar
  72. 72.
    Dorado P, Lopez-Torres E, Penas-Lledo EM, Martinez-Anton J, Llerena A. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. Pharmacogenomics J. 2013;13(4):359–61.PubMedGoogle Scholar
  73. 73.
    Ertan S, Ulu MO, Hanimoglu H, Tanriverdi T, Kafadar AM, Acar ZU, et al. Phenytoin-induced parkinsonism. Singapore Med J. 2006;47(11):981–3.PubMedGoogle Scholar
  74. 74.
    Gannaway DJ, Mawer GE. Serum phenytoin concentration and clinical response in patients with epilepsy. Br J Clin Pharmacol. 1981;12(6):833–9.PubMedCentralPubMedGoogle Scholar
  75. 75.
    Garson A Jr, Kugler JD, Gillette PC, Simonelli A, McNamara DG. Control of late postoperative ventricular arrhythmias with phenytoin in young patients. Am J Cardiol. 1980;46(2):290–4.PubMedGoogle Scholar
  76. 76.
    Gore JM, Haffajee CI, Alpert JS. Interaction of amiodarone and diphenylhydantoin. Am J Cardiol. 1984;54(8):1145.PubMedGoogle Scholar
  77. 77.
    Gupta V, Yadav TP, Yadav A. Phenytoin toxicity presenting as acute meningo-encephalitis in children. Neurol India. 2011;59(1):66–7.PubMedGoogle Scholar
  78. 78.
    Hellden A, Bergman U, Engstrom Hellgren K, Masquelier M, Nilsson Remahl I, Odar-Cederlof I, et al. Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9. Eur J Clin Pharmacol. 2010;66(8):791–5.PubMedGoogle Scholar
  79. 79.
    Imamura T, Ejima A, Sahara M, Saito H, Tsuburaya K. Cerebellar atrophy and persistent cerebellar ataxia after acute intoxication of phenytoin. No To Shinkei Brain Nerve. 1992;44(2):149–53.Google Scholar
  80. 80.
    Kuruvilla T, Bharucha NE. Cerebellar atrophy after acute phenytoin intoxication. Epilepsia. 1997;38(4):500–2.PubMedGoogle Scholar
  81. 81.
    Lindvall O, Nilsson B. Cerebellar atrophy following phenytoin intoxication. Ann Neurol. 1984;16(2):258–60.PubMedGoogle Scholar
  82. 82.
    Lopez-Ariztegui N, Ochoa M, Sanchez-Migallon MJ, Nevado C, Martin M. Acute phenytoin poisoning secondary to an interaction with ticlopidine. Rev Neurol. 1998;26(154):1017–8.PubMedGoogle Scholar
  83. 83.
    Mamiya K, Kojima K, Yukawa E, Higuchi S, Ieiri I, Ninomiya H, et al. Phenytoin intoxication induced by fluvoxamine. Ther Drug Monit. 2001;23(1):75–7.PubMedGoogle Scholar
  84. 84.
    Murphy A, Wilbur K. Phenytoin–diazepam interaction. Ann Pharmacother. 2003;37(5):659–63.Google Scholar
  85. 85.
    Murphy JM, Motiwala R, Devinsky O. Phenytoin intoxication. South Med J. 1991;84(10):1199–204.PubMedGoogle Scholar
  86. 86.
    Robertson K, von Stempel CB, Arnold I. When less is more: a case of phenytoin toxicity. BMJ Case Rep. 2013.Google Scholar
  87. 87.
    Sanchez-Romero A, Duran-Quintana JA, Garcia-Delgado R, Margarito-Rangel C, Poveda-Andres JL. Possible gabapentin phenytoin interaction. Rev Neurol. 2002;34(10):952–3.PubMedGoogle Scholar
  88. 88.
    Sharma S, Dasroy SK. Images in clinical medicine. Gingival hyperplasia induced by phenytoin. N Engl J Med. 2000;342(5):325.PubMedGoogle Scholar
  89. 89.
    Sung SF, Chiang PC, Tung HH, Ong CT. Charcoal hemoperfusion in an elderly man with life-threatening adverse reactions due to poor metabolism of phenytoin. J Formos Med Assoc Taiwan Yi Zhi. 2004;103(8):648–52.Google Scholar
  90. 90.
    Teta D, Uldry PA, Regli F. Reversible ophthalmoplegia, cerebellar syndrome and vigilance disorders following phenytoin poisoning. Schweiz Med Wochenschr. 1990;120(41):1504–7.PubMedGoogle Scholar
  91. 91.
    Wessely P, Mayr N, Binder H, Klingler D. Neurological signs in diphenylhydantoin intoxication (case reports and review; author’s transl). Wien Klin Wochenschr. 1981;93(10):315–21.Google Scholar
  92. 92.
    Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/day for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.PubMedCentralPubMedGoogle Scholar
  93. 93.
    Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004;45(1):20–7.PubMedGoogle Scholar
  94. 94.
    Baulac M, Leon T, O’Brien TJ, Whalen E, Barrett J. A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. Epilepsy Res. 2010;91(1):10–9.PubMedGoogle Scholar
  95. 95.
    Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA, et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology. 2005;64(3):475–80.PubMedGoogle Scholar
  96. 96.
    Choi JY, Park YM, Woo YS, Kim SU, Jung JM, Kwon DY. Perverted head-shaking and positional downbeat nystagmus in pregabalin intoxication. J Neurol Sci. 2014;337(1–2):243–4.PubMedGoogle Scholar
  97. 97.
    Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60(8):1274–83.PubMedGoogle Scholar
  98. 98.
    Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia. 2005;46(12):1926–36.PubMedGoogle Scholar
  99. 99.
    French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose–response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology. 2003;60(10):1631–7.Google Scholar
  100. 100.
    Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63(11):2104–10.PubMedGoogle Scholar
  101. 101.
    Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160(3):533–40.PubMedGoogle Scholar
  102. 102.
    Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004;24(2):141–9.PubMedGoogle Scholar
  103. 103.
    Biton V, Gil-Nagel A, Brodie MJ, Derossett SE, Nohria V. Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures. Epilepsy Res. 2013;107(1–2):138–45.PubMedGoogle Scholar
  104. 104.
    Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall S, Shin P, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology. 2010;75(20):1817–24.PubMedGoogle Scholar
  105. 105.
    French JA, Abou-Khalil BW, Leroy RF, Yacubian EM, Shin P, Hall S, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology. 2011;76(18):1555–63.PubMedGoogle Scholar
  106. 106.
    Chappell AS, Sander JW, Brodie MJ, Chadwick D, Lledo A, Zhang D, et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology. 2002;58(11):1680–2.PubMedGoogle Scholar
  107. 107.
    Langan YM, Lucas R, Jewell H, Toublanc N, Schaefer H, Sander JW, et al. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia. 2003;44(1):46–53.PubMedGoogle Scholar
  108. 108.
    Crawford P, Meinardi H, Brown S, Rentmeester TW, Pedersen B, Pedersen PC, et al. Tiagabine: efficacy and safety in adjunctive treatment of partial seizures. Epilepsia. 2001;42(4):531–8.PubMedGoogle Scholar
  109. 109.
    Vossler DG, Morris GL 3rd, Harden CL, Montouris G, Faught E, Kanner AM, et al. Tiagabine in clinical practice: effects on seizure control and behavior. Epilepsy Behav. 2013;28(2):211–6.PubMedGoogle Scholar
  110. 110.
    Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia. 1996;37(6):539–43.PubMedGoogle Scholar
  111. 111.
    Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology. 1996;46(6):1684–90.PubMedGoogle Scholar
  112. 112.
    Privitera M, Fincham R, Penry J, Reife R, Kramer L, Pledger G, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology. 1996;46(6):1678–83.PubMedGoogle Scholar
  113. 113.
    Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia. 2000;41(Suppl 1):S66–71.PubMedGoogle Scholar
  114. 114.
    Rosenfeld WE, Sachdeo RC, Faught RE, Privitera M. Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: retrospective survey of open-label treatment. Epilepsia. 1997;38(Suppl 1):S34–6.PubMedGoogle Scholar
  115. 115.
    Tassinari CA, Michelucci R, Chauvel P, Chodkiewicz J, Shorvon S, Henriksen O, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia. 1996;37(8):763–8.PubMedGoogle Scholar
  116. 116.
    Bos MJ, de Weerd AW, Hagebeuk EE. Staring episodes in children with developmental disorders: epilepsy or behaviour? Ned Tijdschr Geneeskd. 2011;155:A2473.PubMedGoogle Scholar
  117. 117.
    Chan K, Beran RG. Value of therapeutic drug level monitoring and unbound (free) levels. Seizure. 2008;17(6):572–5.PubMedGoogle Scholar
  118. 118.
    Ellaway CJ, Bennetts B, Tuck RR, Wilcken B. Clumsiness, confusion, coma, and valproate. Lancet. 1999;353(9162):1408.PubMedGoogle Scholar
  119. 119.
    Fisk GG, York SM. The effect of sodium valproate on tardive dyskinesia—revisited. Br J Psychiatry. 1987;150:542–6.Google Scholar
  120. 120.
    Gomceli YB, Kutlu G, Cavdar L, Sanivar F, Inan LE. Different clinical manifestations of hyperammonemic encephalopathy. Epilepsy Behav. 2007;10(4):583–7.PubMedGoogle Scholar
  121. 121.
    Hamer HM, Knake S, Schomburg U, Rosenow F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology. 2000;54(1):230–2.PubMedGoogle Scholar
  122. 122.
    Hommet C, Mondon K, de Toffol B, Constans T. Reversible cognitive and neurological symptoms during valproic acid therapy. J Am Geriatr Soc. 2007;55(4):628.PubMedGoogle Scholar
  123. 123.
    Kifune A, Kubota F, Shibata N, Akata T, Kikuchi S. Valproic acid-induced hyperammonemic encephalopathy with triphasic waves. Epilepsia. 2000;41(7):909–12.PubMedGoogle Scholar
  124. 124.
    Osuna MT, Burcet J, Ramio L, Ustrell X, Silva Y, Molins A. Hyperammonemic encephalopathy associated with valproate acid. Neurologia. 2003;18(6):347–50.PubMedGoogle Scholar
  125. 125.
    Panda S, Radhakrishnan K. Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure. J Assoc Phys India. 2004;52:746–8.Google Scholar
  126. 126.
    Richens A, Ahmad S. Controlled trial of sodium valproate in severe epilepsy. Br Med J. 1975;4(5991):255–6.PubMedCentralPubMedGoogle Scholar
  127. 127.
    Rottach KG, Weiss-Brummer J, Wieland U, Schmauss M. Valproic acid in prophylaxis of bipolar disorder. A case of valproate-induced encephalopathy. Der Nervenarzt. 2000;71(5):401–3.PubMedGoogle Scholar
  128. 128.
    Schwartz TH, Karpitskiy VV, Sohn RS. Intravenous valproate sodium in the treatment of daily headache. Headache. 2002;42(6):519–22.PubMedGoogle Scholar
  129. 129.
    Vossler DG, Wilensky AJ, Cawthon DF, Kraemer DL, Ojemann LM, Caylor LM, et al. Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy. Epilepsia. 2002;43(2):154–9.PubMedGoogle Scholar
  130. 130.
    Zaccara G, Paganini M, Campostrini R, Arnetoli G, Zappoli R, Moroni F. Hyperammonemia and valproate-induced alterations of the state of consciousness. A report of 8 cases. Eur Neurol. 1984;23(2):104–12.PubMedGoogle Scholar
  131. 131.
    Single-blind, placebo-controlled multicenter trial of vigabatrin in the treatment of epilepsy. The Italian Study Group on Vigabatrin. Ital J Neurol Sci. 1992;13(9):741–7.Google Scholar
  132. 132.
    Armour DJ, Fidler C, Wright EC, Balarajan S. Vigabatrin in adults with poorly-controlled epilepsy and learning disabilities. Seizure. 1992;1(3):157–62.PubMedGoogle Scholar
  133. 133.
    Beran RG, Berkovic SF, Buchanan N, Danta G, Mackenzie R, Schapel G, et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure. 1996;5(4):259–65.PubMedGoogle Scholar
  134. 134.
    Browne TR, Mattson RH, Penry JK, Smith DB, Treiman DM, Wilder BJ, et al. A multicentre study of vigabatrin for drug-resistant epilepsy. Br J Clin Pharmacol. 1989;27(Suppl 1):95S–100S.PubMedCentralPubMedGoogle Scholar
  135. 135.
    Cocito L, Maffini M, Perfumo P, Roncallo F, Loeb C. Vigabatrin in complex partial seizures: a long-term study. Epilepsy Res. 1989;3(2):160–6.PubMedGoogle Scholar
  136. 136.
    Dean C, Mosier M, Penry K. Dose-response study of Vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia. 1999;40(1):74–82.Google Scholar
  137. 137.
    Gram L, Klosterskov P, Dam M. Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Ann Neurol. 1985;17(3):262–6.PubMedGoogle Scholar
  138. 138.
    Livingston JH, Beaumont D, Arzimanoglou A, Aicardi J. Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharmacol. 1989;27(Suppl 1):109S–12S.PubMedCentralPubMedGoogle Scholar
  139. 139.
    Matilainen R, Pitkanen A, Ruutiainen T, Mervaala E, Riekkinen P. Vigabatrin in epilepsy in mentally retarded patients. Br J Clin Pharmacol. 1989;27(Suppl 1):113S–8S.PubMedCentralPubMedGoogle Scholar
  140. 140.
    Sharief MK, Sander JW, Shorvon SD. Acute encephalopathy with vigabatrin. Lancet. 1993;342(8871):619.PubMedGoogle Scholar
  141. 141.
    Tartara A, Manni R, Galimberti CA, Mumford JP, Iudice A, Perucca E. Vigabatrin in the treatment of epilepsy: a long-term follow-up study. J Neurol Neurosurg Psychiatry. 1989;52(4):467–71.PubMedCentralPubMedGoogle Scholar
  142. 142.
    Faught E, Ayala R, Montouris GG, Leppik IE. Zonisamide 922 Trial G. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. 2001;57(10):1774–9.PubMedGoogle Scholar
  143. 143.
    Leppik IE, Willmore LJ, Homan RW, Fromm G, Oommen KJ, Penry JK, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res. 1993;14(2):165–73.PubMedGoogle Scholar
  144. 144.
    Sackellares JC, Ramsay RE, Wilder BJ, Browne TR 3rd, Shellenberger MK. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia. 2004;45(6):610–7.PubMedGoogle Scholar
  145. 145.
    Schmidt D, Jacob R, Loiseau P, Deisenhammer E, Klinger D, Despland A, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 1993;15(1):67–73.PubMedGoogle Scholar
  146. 146.
    Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–15.PubMedCentralPubMedGoogle Scholar
  147. 147.
    Sirven JI, Fife TD, Wingerchuk DM, Drazkowski JF. Second-generation antiepileptic drugs’ impact on balance: a meta-analysis. Mayo Clin Proc. 2007;82(1):40–7.PubMedGoogle Scholar
  148. 148.
    Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure. 2008;17(5):405–21.PubMedGoogle Scholar
  149. 149.
    Zaccara G, Giovannelli F, Maratea D, Fadda V, Verrotti A. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Seizure. 2013;22(7):528–36.PubMedGoogle Scholar
  150. 150.
    Craig S. Phenytoin poisoning. Neurocrit Care. 2005;3(2):161–70.PubMedGoogle Scholar
  151. 151.
    Aylett SE, Cross H, Berry D. Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy. Dev Med Child Neurol. 2006;48(7):612–5.PubMedGoogle Scholar
  152. 152.
    Kalra V, Seth R, Mishra D, Saha NC. Clobazam in refractory childhood epilepsy. Indian J Pediatr. 2010;77(3):263–6.PubMedGoogle Scholar
  153. 153.
    Mehndiratta MM, Krishnamurthy M, Rajesh KN, Singh G. Clobazam monotherapy in drug naive adult patients with epilepsy. Seizure. 2003;12(4):226–8.PubMedGoogle Scholar
  154. 154.
    Rose W, Kirubakaran C, Scott JX. Intermittent clobazam therapy in febrile seizures. Indian J Pediatr. 2005;72(1):31–3.PubMedGoogle Scholar
  155. 155.
    Wolf P. Acute administration of benzodiazepines as part of treatment strategies for epilepsy. CNS Neurosci Ther. 2011;17(4):214–20.PubMedGoogle Scholar
  156. 156.
    Dreifuss FE, Penry JK, Rose SW, Kupferberg HJ, Dyken P, Sato S. Serum clonazepam concentrations in children with absence seizures. Neurology. 1975;25(3):255–8.PubMedGoogle Scholar
  157. 157.
    Dixon RA, Bennett NR, Harrison MJ, Kenyon C, Thornton JA. I.v. flunitrazepam and i.v. diazepam in conservative dentistry. A cross-over trial. Br J Anaesth. 1980;52(5):517–26.PubMedGoogle Scholar
  158. 158.
    Maltby JR, Hamilton RC, Phillips R. Comparison of flunitrazepam and thiopentone for induction of general anaesthesia. Can Anaesth Soc J. 1980;27(4):331–7.PubMedGoogle Scholar
  159. 159.
    Jan JE, Riegl JA, Crichton JU, Dunn HG. Nitrazepam in the treatmet of epilepsy in childhood. Can Med Assoc J. 1971;104(7):571–5.PubMedCentralPubMedGoogle Scholar
  160. 160.
    Coldwell SE, Awamura K, Milgrom P, Depner KS, Kaufman E, Preston KL, et al. Side effects of triazolam in children. Pediatr Dent. 1999;21(1):18–25.PubMedGoogle Scholar
  161. 161.
    Raadal M, Coldwell SE, Kaakko T, Milgrom P, Weinstein P, Perkis V, et al. A randomized clinical trial of triazolam in 3- to 5-year-olds. J Dent Res. 1999;78(6):1197–203.PubMedGoogle Scholar
  162. 162.
    Tweedy CM, Milgrom P, Kharasch ED, Kaakko T, Spieker M, Coldwell SE. Pharmacokinetics and clinical effects of sublingual triazolam in pediatric dental patients. J Clin Psychopharmacol. 2001;21(3):268–72.PubMedGoogle Scholar
  163. 163.
    Kerry RJ, McDermott CM, Orme JE. Bromazepam, medazepam, chlordiazepoxide in treatment of neurotic anxiety. Br J Psychiatry. 1974;124:485–6.PubMedGoogle Scholar
  164. 164.
    Adityanjee. The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT). Pharmacopsychiatry. 1989;22(2):81–3.PubMedGoogle Scholar
  165. 165.
    Andrade C, Gangadhar BN, Channabasavanna SM. Pathological neurotoxicity with lithium. Indian J Psychiatry. 1987;29(3):279–81.PubMedCentralPubMedGoogle Scholar
  166. 166.
    Apte SN, Langston JW. Permanent neurological deficits due to lithium toxicity. Ann Neurol. 1983;13(4):453–5.PubMedGoogle Scholar
  167. 167.
    Arya DK. Lithium-induced neurotoxicity at serum lithium levels within the therapeutic range. Aust NZ J Psychiatry. 1996;30(6):871–3.Google Scholar
  168. 168.
    Blanche P, Raynaud E, Kerob D, Galezowski N. Lithium intoxication in an elderly patient after combined treatment with losartan. Eur J Clin Pharmacol. 1997;52(6):501.PubMedGoogle Scholar
  169. 169.
    Cerqueira AC, Reis MC, Novis FD, Bezerra JM, Magalhaes GC, Rozenthal M, et al. Cerebellar degeneration secondary to acute lithium carbonate intoxication. Arq Neuropsiquiatr. 2008;66(3A):578–80.PubMedGoogle Scholar
  170. 170.
    Cohen WJ, Cohen NH. Lithium carbonate, haloperidol, and irreversible brain damage. JAMA. 1974;230(9):1283–7.PubMedGoogle Scholar
  171. 171.
    Dembowski C, Rechlin T. Successful antimanic treatment and mood stabilization with lamotrigine, clozapine, and valproate in a bipolar patient after lithium-induced cerebellar deterioration. A case report. Pharmacopsychiatry. 2003;36(2):83–6.PubMedGoogle Scholar
  172. 172.
    Dennison U, Clarkson M, O’Mullane J, Cassidy EM. The incidence and clinical correlates of lithium toxicity: a retrospective review. Ir J Med Sci. 2011;180(3):661–5.PubMedGoogle Scholar
  173. 173.
    Donaldson IM, Cuningham J. Persisting neurologic sequelae of lithium carbonate therapy. Arch Neurol. 1983;40(12):747–51.PubMedGoogle Scholar
  174. 174.
    Ferbert A, Czernik A. Persistent cerebellar syndrome following lithium poisoning. Der Nervenarzt. 1987;58(12):764–70.PubMedGoogle Scholar
  175. 175.
    Green JB. Permanent neurological deficits resulting from lithium toxicity. Ann Neurol. 1984;15(1):111.PubMedGoogle Scholar
  176. 176.
    Ilagan MC, Carlson D, Madden JF. Lithium toxicity: two case reports. Del Med J. 2002;74(6):263–70.PubMedGoogle Scholar
  177. 177.
    Johnson GF. Lithium neurotoxicity. Aust NZ J Psychiatry. 1976;10(1):33–8.Google Scholar
  178. 178.
    Lang EJ, Davis SM. Lithium neurotoxicity: the development of irreversible neurological impairment despite standard monitoring of serum lithium levels. J Clin Neurosci. 2002;9(3):308–9.PubMedGoogle Scholar
  179. 179.
    Lewis DA. Unrecognized chronic lithium neurotoxic reactions. JAMA. 1983;250(15):2029–30.PubMedGoogle Scholar
  180. 180.
    Manto M, Godaux E, Jacquy J, Hildebrand JG. Analysis of cerebellar dysmetria associated with lithium intoxication. Neurol Res. 1996;18(5):416–24.PubMedGoogle Scholar
  181. 181.
    Nagaraja D, Taly AB, Sahu RN, Channabasavanna SM, Narayanan HS. Permanent neurological sequelae due to lithium toxicity. Clin Neurol Neurosurg. 1987;89(1):31–4.PubMedGoogle Scholar
  182. 182.
    Niethammer M, Ford B. Permanent lithium-induced cerebellar toxicity: three cases and review of literature. Mov Disord. 2007;22(4):570–3.PubMedGoogle Scholar
  183. 183.
    Ozsoy S, Basturk M, Esel E. Cerebellar syndrome in a patient with pneumonia under lithium treatment: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(8):1532–4.PubMedGoogle Scholar
  184. 184.
    Prettyman R. Lithium neurotoxicity at subtherapeutic serum levels. Br J Psychiatry. 1994;164(1):123.PubMedGoogle Scholar
  185. 185.
    Schneider JA, Mirra SS. Neuropathologic correlates of persistent neurologic deficit in lithium intoxication. Ann Neurol. 1994;36(6):928–31.PubMedGoogle Scholar
  186. 186.
    Sellers J, Tyrer P, Whiteley A, Banks DC, Barer DH. Neurotoxic effects of lithium with delayed rise in serum lithium levels. Br J Psychiatry. 1982;140:623–5.PubMedGoogle Scholar
  187. 187.
    Singh SV. Lithium carbonate/fluphenazine decanoate producing irreversible brain damage. Lancet. 1982;2(8292):278.PubMedGoogle Scholar
  188. 188.
    Uchigata M, Tanabe H, Hasue I, Kurihara M. Peripheral neuropathy due to lithium intoxication. Ann Neurol. 1981;9(4):414.PubMedGoogle Scholar
  189. 189.
    Verdoux H, Bourgeois ML. A case of lithium neurotoxicity with irreversible cerebellar syndrome. J Nerv Ment Dis. 1990;178(12):761–2.PubMedGoogle Scholar
  190. 190.
    Von Hartitzsch B, Hoenich NA, Leigh RJ, Wilkinson R, Frost TH, Weddel A, et al. Permanent neurological sequelae despite haemodialysis for lithium intoxication. Br Med J. 1972;4(5843):757–9.Google Scholar
  191. 191.
    Vredeveld CJ, Morre HH. Lithium neurotoxicity in advanced age. 2 case reports with a literature review. Der Nervenarzt. 1983;54(7):377–80.PubMedGoogle Scholar
  192. 192.
    Kores B, Lader MH. Irreversible lithium neurotoxicity: an overview. Clin Neuropharmacol. 1997;20(4):283–99.PubMedGoogle Scholar
  193. 193.
    Adityanjee, Munshi KR, Thampy A. The syndrome of irreversible lithium-effectuated neurotoxicity. Clin Neuropharmacol. 2005;28(1):38–49.PubMedGoogle Scholar
  194. 194.
    Boesen P, Fallingborg J, Spaun E. Severe persistent cerebellar dysfunction complicating cytosine arabinoside therapy. Acta Med Scand. 1988;224(2):189–91.PubMedGoogle Scholar
  195. 195.
    Dworkin LA, Goldman RD, Zivin LS, Fuchs PC. Cerebellar toxicity following high-dose cytosine arabinoside. J Clin Oncol. 1985;3(5):613–6.PubMedGoogle Scholar
  196. 196.
    Early AP, Preisler HD, Slocum H, Rustum YM. A pilot study of high-dose 1-β-d-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res. 1982;42(4):1587–94.Google Scholar
  197. 197.
    Friedman JH, Shetty N. Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman. Mov Disord. 2001;16(3):575–7.PubMedGoogle Scholar
  198. 198.
    Gottlieb D, Bradstock K, Koutts J, Robertson T, Lee C, Castaldi P. The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer. 1987;60(7):1439–41.PubMedGoogle Scholar
  199. 199.
    Grossman L, Baker MA, Sutton DM, Deck JH. Central nervous system toxicity of high-dose cytosine arabinoside. Med Pediatr Oncol. 1983;11(4):246–50.PubMedGoogle Scholar
  200. 200.
    Hasle H. Cerebellar toxicity during cytarabine therapy associated with renal insufficiency. Cancer Chemother Pharmacol. 1990;27(1):76–8.PubMedGoogle Scholar
  201. 201.
    Herzig RH, Hines JD, Herzig GP, Wolff SN, Cassileth PA, Lazarus HM, et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol. 1987;5(6):927–32.PubMedGoogle Scholar
  202. 202.
    Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer. 1981;48(12):2577–82.PubMedGoogle Scholar
  203. 203.
    Nand S, Messmore HL Jr, Patel R, Fisher SG, Fisher RI. Neurotoxicity associated with systemic high-dose cytosine arabinoside. J Clin Oncol. 1986;4(4):571–5.PubMedGoogle Scholar
  204. 204.
    Salinsky MC, Levine RL, Aubuchon JP, Schutta HS. Acute cerebellar dysfunction with high-dose ARA-C therapy. Cancer. 1983;51(3):426–9.PubMedGoogle Scholar
  205. 205.
    Sylvester RK, Fisher AJ, Lobell M. Cytarabine-induced cerebellar syndrome: case report and literature review. Drug Intell Clin Pharm. 1987;21(2):177–80.PubMedGoogle Scholar
  206. 206.
    Winkelman MD, Hines JD. Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol. 1983;14(5):520–7.PubMedGoogle Scholar
  207. 207.
    Yeshurun M, Marsot Dupuch K. Acute cerebellar syndrome following intermediate-dose cytarabine. Br J Haematol. 2001;113(4):846.PubMedGoogle Scholar
  208. 208.
    Pazdur R, Ajani JA, Winn R, Bearden J, Belt RJ, Pilat S, et al. A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma. Cancer. 1992;69(4):878–82.PubMedGoogle Scholar
  209. 209.
    Saltz L, Kemeny N, Schwartz G, Kelsen D. A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer. 1994;74(3):958–61.PubMedGoogle Scholar
  210. 210.
    Stuart K, Tessitore J, Huberman M. 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma. Am J Clin Oncol. 1996;19(2):136–9.PubMedGoogle Scholar
  211. 211.
    Kaleyias J, Faerber E, Kothare SV. Tacrolimus induced subacute cerebellar ataxia. Eur J Paediatr Neurol. 2006;10(2):86–9.PubMedGoogle Scholar
  212. 212.
    Ponseti JM, Azem J, Fort JM, Lopez-Cano M, Vilallonga R, Buera M, et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology. 2005;64(9):1641–3.PubMedGoogle Scholar
  213. 213.
    Ringelstein A, Bongs K, Sorge-Hadicke B, Berlit P. Case of inflammatory vasculopathy and encephalopathy caused by treatment with tacrolimus. Der Nervenarzt. 2005;76(4):475–8.PubMedGoogle Scholar
  214. 214.
    Sokol DK, Molleston JP, Filo RS, Van Valer J, Edwards-Brown M. Tacrolimus (FK506)-induced mutism after liver transplant. Pediatr Neurol. 2003;28(2):156–8.PubMedGoogle Scholar
  215. 215.
    Yamaguchi I, Ichikawa T, Nakao K, Hamasaki K, Hirano K, Eguchi S, et al. Cerebellar ataxia in a patient receiving calcineurin inhibitors after living donor liver transplantation: a case report. Transpl Proc. 2007;39(10):3495–7.Google Scholar
  216. 216.
    Baz DV, Bofill JS, Nogueira JA. Irinotecan-induced dysarthria. J Natl Cancer Inst. 2001;93(18):1419–20.PubMedGoogle Scholar
  217. 217.
    De Marco S, Squilloni E, Vigna L, Bertagnolio MF, Sternberg CN. Irinotecan chemotherapy associated with transient dysarthria and aphasia. Ann Oncol. 2004;15(7):1147–8.PubMedGoogle Scholar
  218. 218.
    Hamberg P, De Jong FA, Brandsma D, Verweij J, Sleijfer S. Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature. Acta Oncol. 2008;47(5):974–8.PubMedGoogle Scholar
  219. 219.
    Hamberg P, Donders RC, ten Bokkel Huinink D. Central nervous system toxicity induced by irinotecan. J Natl Cancer Inst. 2006;98(3):219.PubMedGoogle Scholar
  220. 220.
    Atkinson K, Biggs J, Darveniza P, Boland J, Concannon A, Dodds A. Spinal cord and cerebellar-like syndromes associated with the use of cyclosporine in human recipients of allogeneic marrow transplants. Transpl Proc. 1985;17(2):1673–5.Google Scholar
  221. 221.
    Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int. 2000;13(5):313–26.PubMedGoogle Scholar
  222. 222.
    Belli LS, De Carlis L, Romani F, Rondinara GF, Rimoldi P, Alberti A, et al. Dysarthria and cerebellar ataxia: late occurrence of severe neurotoxicity in a liver transplant recipient. Transpl Int. 1993;6(3):176–8.PubMedGoogle Scholar
  223. 223.
    Nussbaum ES, Maxwell RE, Bitterman PB, Hertz MI, Bula W, Latchaw RE. Cyclosporine A toxicity presenting with acute cerebellar edema and brainstem compression. J Neurosurg. 1995;82(6):1068–70.PubMedGoogle Scholar
  224. 224.
    Porges Y, Blumen S, Fireman Z, Sternberg A, Zamir D. Cyclosporine-induced optic neuropathy, ophthalmoplegia, and nystagmus in a patient with Crohn disease. Am J Ophthalmol. 1998;126(4):607–9.PubMedGoogle Scholar
  225. 225.
    Vogt DP, Lederman RJ, Carey WD, Broughan TA. Neurologic complications of liver transplantation. Transplantation. 1988;45(6):1057–61.PubMedGoogle Scholar
  226. 226.
    Ardalan B, Singh G, Silberman H. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-l-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol. 1988;6(6):1053–8.PubMedGoogle Scholar
  227. 227.
    Atkins JN, Muss HB, Case D, Brockschmidt J, Schnell FM, O’Rourke M, et al. High-dose 24-h infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol. 1991;14(6):526–9.PubMedGoogle Scholar
  228. 228.
    Gottlieb JA, Luce JK. Cerebellar ataxia with weekly 5-fluorouracil administration. Lancet. 1971;1(7690):138–9.PubMedGoogle Scholar
  229. 229.
    Hansen R, Quebbeman E, Ritch P, Chitambar C, Anderson T. Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: a phase II study. Am J Med Sci. 1988;295(2):91–3.PubMedGoogle Scholar
  230. 230.
    Huan S, Pazdur R, Singhakowinta A, Samal B, Vaitkevicius VK. Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma. Cancer. 1989;63(3):419–22.PubMedGoogle Scholar
  231. 231.
    Moertel CG, Reitemeier RJ, Bolton CF, Shorter RG. Cerebellar ataxia associated with fluorinated pyrimidine therapy. Cancer Chemother Rep Part 1. 1964;41:15–8.Google Scholar
  232. 232.
    Pirzada NA, Ali II, Dafer RM. Fluorouracil-induced neurotoxicity. Ann Pharmacother. 2000;34(1):35–8.PubMedGoogle Scholar
  233. 233.
    Sorensen P, Andersen LJ, Hansen O, Bastholt L. Long-term continuous 5-fluorouracil infusion in patients with advanced head and neck cancer. Acta Oncol. 1999;38(8):1043–5.PubMedGoogle Scholar
  234. 234.
    Bollen E, Lanser JB. Reversible mental deterioration and neurological disturbances with o,p′-DDD therapy. Clin Neurol Neurosurg. 1992;94(Suppl):S49–51.Google Scholar
  235. 235.
    Perry JR, Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology. 1996;46(6):1596–9.PubMedGoogle Scholar
  236. 236.
    Thompson CB, June CH, Sullivan KM, Thomas ED. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet. 1984;2(8412):1116–20.PubMedGoogle Scholar
  237. 237.
    Charness ME, Morady F, Scheinman MM. Frequent neurologic toxicity associated with amiodarone therapy. Neurology. 1984;34(5):669–71.PubMedGoogle Scholar
  238. 238.
    Coulter DM, Edwards IR, Savage RL. Survey of neurological problems with amiodarone in the New Zealand Intensive Medicines Monitoring Programme. NZ Med J. 1990;103(885):98–100.Google Scholar
  239. 239.
    Fogoros RN, Anderson KP, Winkle RA, Swerdlow CD, Mason JW. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation. 1983;68(1):88–94.PubMedGoogle Scholar
  240. 240.
    Garretto NS, Rey RD, Kohler G, Cocorullo S, Monteverde DA, Ravera BI, et al. Cerebellar syndrome caused by amiodarone. Arq Neuropsiquiatr. 1994;52(4):575–7.PubMedGoogle Scholar
  241. 241.
    Greene HL, Graham EL, Werner JA, Sears GK, Gross BW, Gorham JP, et al. Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol. 1983;2(6):1114–28.PubMedGoogle Scholar
  242. 242.
    Hindle JV, Ibrahim A, Ramaraj R. Ataxia caused by amiodarone in older people. Age Ageing. 2008;37(3):347–8.PubMedGoogle Scholar
  243. 243.
    Krauser DG, Segal AZ, Kligfield P. Severe ataxia caused by amiodarone. Am J Cardiol. 2005;96(10):1463–4.PubMedGoogle Scholar
  244. 244.
    McGovern B, Garan H, Kelly E, Ruskin JN. Adverse reactions during treatment with amiodarone hydrochloride. Br Med J (Clin Res Ed). 1983;287(6386):175–80.Google Scholar
  245. 245.
    Morady F, Sauve MJ, Malone P, Shen EN, Schwartz AB, Bhandari A, et al. Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol. 1983;52(8):975–9.PubMedGoogle Scholar
  246. 246.
    Morady F, Scheinman MM, Hess DS. Amiodarone in the management of patients with ventricular tachycardia and ventricular fibrillation. Pacing Clin Electrophysiol. 1983;6(3 Pt 1):609–15.PubMedGoogle Scholar
  247. 247.
    Onofrj M, Thomas A. Acetazolamide-responsive periodic ataxia induced by amiodarone. Mov Disord. 1999;14(2):379–81.PubMedGoogle Scholar
  248. 248.
    Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol. 2009;66(7):865–9.PubMedGoogle Scholar
  249. 249.
    Palakurthy PR, Iyer V, Meckler RJ. Unusual neurotoxicity associated with amiodarone therapy. Arch Intern Med. 1987;147(5):881–4.PubMedGoogle Scholar
  250. 250.
    Willis MS, Lugo AM. Amiodarone-induced neurotoxicity. Am J Health Syst Pharm. 2009;66(6):567–9.PubMedGoogle Scholar
  251. 251.
    Odeh M, Seligmann H, Oliven A. Propafenone-induced ataxia: report of three cases. Am J Med Sci. 2000;320(2):151–3.PubMedGoogle Scholar
  252. 252.
    Ohara S, Hayashi R, Momoi H, Miki J, Yanagisawa N. Mexiletine in the treatment of spasmodic torticollis. Mov Disord. 1998;13(6):934–40.PubMedGoogle Scholar
  253. 253.
    Bosso JA, Liptak CA, Seilheimer DK, Harrison GM. Toxicity of colistin in cystic fibrosis patients. DICP. 1991;25(11):1168–70.PubMedGoogle Scholar
  254. 254.
    Prevoznik SJ. Truncal ataxia as a complication of colistin therapy: its relation to spinal anesthesia. Anesth Analg. 1967;46(1):46–8.PubMedGoogle Scholar
  255. 255.
    Chacko J, Pramod K, Sinha S, Saini J, Mahadevan A, Bharath RD, et al. Clinical, neuroimaging and pathological features of 5-nitroimidazole-induced encephalo-neuropathy in two patients: insights into possible pathogenesis. Neurol India. 2011;59(5):743–7.Google Scholar
  256. 256.
    Graves TD, Condon M, Loucaidou M, Perry RJ. Reversible metronidazole-induced cerebellar toxicity in a multiple transplant recipient. J Neurol Sci. 2009;285(1–2):238–40.PubMedGoogle Scholar
  257. 257.
    Hari A, Srikanth BA, Lakshmi GS. Metronidazole induced cerebellar ataxia. Indian J Pharmacol. 2013;45(3):295–7.PubMedCentralPubMedGoogle Scholar
  258. 258.
    Heaney CJ, Campeau NG, Lindell EP. MR imaging and diffusion-weighted imaging changes in metronidazole (Flagyl)-induced cerebellar toxicity. Am J Neuroradiol. 2003;24(8):1615–7.PubMedGoogle Scholar
  259. 259.
    Iqbal A, Tripathi K, Rai M, Dwivedi AN. Clinical and imaging perspective and unanswered questions in a case of metronidazole induced encephalopathy. Ann Indian Acad Neurol. 2013;16(4):569–71.PubMedCentralPubMedGoogle Scholar
  260. 260.
    Kafadar I, Moustafa F, Yalcn K, Klc BA. A rare adverse effect of metronidazole: nervous system symptoms. Pediatr Emerg Care. 2013;29(6):751–2.PubMedGoogle Scholar
  261. 261.
    Moosa AN, Perkins D. Neurological picture. MRI of metronidazole induced cerebellar ataxia. J Neurol Neurosurg Psychiatry. 2010;81(7):754–5.PubMedGoogle Scholar
  262. 262.
    Park KI, Chung JM, Kim JY. Metronidazole neurotoxicity: sequential neuroaxis involvement. Neurol India. 2011;59(1):104–7.PubMedGoogle Scholar
  263. 263.
    Patel K, Green-Hopkins I, Lu S, Tunkel AR. Cerebellar ataxia following prolonged use of metronidazole: case report and literature review. Int J Infect Dis. 2008;12(6):e111–4.PubMedGoogle Scholar
  264. 264.
    Simonetta F, Christou F, Vandoni RE, Nierle T. Walking unsteadily: a case of acute cerebellar ataxia. BMJ Case Rep. 2013.Google Scholar
  265. 265.
    Takase K, Santa Y, Ohta S, Yoshimura T. MRI and SPECT findings in a case of metronidazole-induced reversible acute cerebellar ataxia. Rinsho Shinkeigaku Clin Neurol. 2005;45(5):386–9.Google Scholar
  266. 266.
    Tan CH, Chen YF, Chen CC, Chao CC, Liou HH, Hsieh ST. Painful neuropathy due to skin denervation after metronidazole-induced neurotoxicity. J Neurol Neurosurg Psychiatry. 2011;82(4):462–5.PubMedGoogle Scholar
  267. 267.
    Woodruff BK, Wijdicks EF, Marshall WF. Reversible metronidazole-induced lesions of the cerebellar dentate nuclei. N Engl J Med. 2002;346(1):68–9.PubMedGoogle Scholar
  268. 268.
    Conners GP. Piperazine neurotoxicity: worm wobble revisited. J Emerg Med. 1995;13(3):341–3.PubMedGoogle Scholar
  269. 269.
    Miller CG, Carpenter R. Neurotoxic side-effects of piperazine. Lancet. 1967;1(7495):895–6.PubMedGoogle Scholar
  270. 270.
    Parsons AC. Piperazine neurotoxicity: “worm wobble”. Br Med J. 1971;4(5790):792.PubMedCentralPubMedGoogle Scholar
  271. 271.
    Sethi AS, Jain AM, Chawla V. Piperazine toxicity. Report of a case. Indian J Pediatr. 1968;35(244):237–8.PubMedGoogle Scholar
  272. 272.
    Shroff R, Houston B. Unusual cerebellar ataxia: “worm wobble” revisited. Arch Dis Child. 2002;87(4):333–4.PubMedCentralPubMedGoogle Scholar
  273. 273.
    Taskapilioglu O, Seferoglu M, Kaygili E, Hakyemez B, Zarifoglu M. Reversible cerebellar toxicity during treatment with ornidazole: the first case report. J Neurol Neurosurg Psychiatry. 2010;81(3):349–50.PubMedGoogle Scholar
  274. 274.
    Bendiksen A, Larsen LM. Convulsions, ataxia and hallucinations following propofol. Acta Anaesthesiol Scand. 1998;42(6):739–41.PubMedGoogle Scholar
  275. 275.
    Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med. 1984;101(1):92–104.PubMedGoogle Scholar
  276. 276.
    Sarna JR, Furtado S, Brownell AK. Neurologic complications of metronidazole. Can J Neurol Sci. 2013;40(6):768–76.PubMedGoogle Scholar
  277. 277.
    Zaccara G, Sisodiya SM, Giovannelli F, Walker MC, Heaney DC, Angus-Leppan H, et al. Network meta-analysis and the comparison of efficacy and tolerability of anti-epileptic drugs for treatment of refractory focal epilepsy. Br J Clin Pharmacol. 2013;76(5):827–8.PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • J. van Gaalen
    • 1
  • F. G. Kerstens
    • 1
  • R. P. P. W. M. Maas
    • 1
  • L. Härmark
    • 2
  • B. P. C. van de Warrenburg
    • 1
  1. 1.Department of Neurology 935 and Donders Institute for Brain, Cognition, and BehaviourRadboud University Medical CentreNijmegenThe Netherlands
  2. 2.Netherlands Pharmacovigilance Centre Lareb’s-HertogenboschThe Netherlands

Personalised recommendations